Stock with a bright future
Cellceutix yearly progress
2011
Q1 2011 Market Cap 36.58 MM
2012
Q1 2012 Market Cap 47.55 MM
October 8 2012 Initiates the Phase I D-F trials for Kevetrin
2013
Q1 2013 Market Cap 165.52 MM
June 3 2013 Presented poster ASCO Kevetrin
June 17 2013 Stability test for Purisol tablets
September 15 2013 Aquires Polymedix
October 2 2013 IND new Psoriasis drug Prurisol
2014
February 24 2014 Brilacidin ophthalmic and otitis formulations started
February 25 2014 First patients 2b ABSSI enrolled
March 19 2014 Seventh cohort for Kevetrin initiated
March 24 2014 Initiates clinical trials for Prurisol
Q1 2014 Market Cap 173.64
May 5 2014 Prurisol completes first cohort
June 16 2014 Eight cohort entering for Kevetrin
July 18 2014 Breakthrough formulation for Brilacidin
Aug 07 2014 Prurisol primary end point met
Sept 19 2014 IND filed Brilacidin OM
Oct 23 2014 IND Brilacidin OM becomes effective
Oct 31 2014 Positive Top Line data regarding Brilicidin phII b
December 10 2014 Brilacidin QIPD designation
December 22 2014 Psoriasis FDA aproves initiation phII
Q1 2015 Market Cap 400 +
Jan 05 2015 Brilacidin confidence intervals revealed
Jan 20 2015 Kevetrin 10th cohort commenced 450mg/m2
Jan 26 2015 Meeting lawyers for Nasdaq listing. New pre-IND for gastrointestinal decease. FDA meeting requested
CTIX upcoming events within weeks
1) Much awaited P21 data reported through 10th cohort.
2) 10th cohort completion and launch of super potent 11th (likely MTD).
3) Add'l Brilacidin data compiled and submitted to FDA.
4) Phase 3 B-ABSSSI meeting and trial approval.
5) Fast Track/Priority Review/5 Yr exclus. approval stemming from meeting.
6) Nasdaq Capital Market Uplisting approval and transition.
7) Stellar and reputable BOD announcements
8) B-OM trial UP and RUNNING!!!
9) Ulcerative Proctitis pre-IND FDA meeting
10) Prurisol Phase 2 Trial Commencement (unclear, but quite possible).
11) Coverage initiation (strong buy) by one or more institutional research analysts.
12) And controversially, but biggest of all, some sort of BIG PHARMA partnership deal for Brilacidin post FDA Meeting.
De reir a cheile a thogtar na caisleain
